ArticleBMJ global health2026
Orchestrating faster access to products of non-profit R&D: a case study of a novel regimen for drug-resistant tuberculosis.
Article in BMJ global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNon-profit product development partnerships (PDPs) have succeeded in bringing nearly 80 new drugs, vaccines and diagnostics for neglected diseases through regulatory approval, but arrangements to ensure they reach patients are unclear since the usual commercial incentives do not apply. We conducted a case study of how unusually fast access was achieved to a new treatment regimen for drug-resistant tuberculosis (DR-TB) developed by the TB Alliance (TBA). Over 100 countries procured the regimen in quantities to reach 67% of global demand by 2024, 5 years after first regulatory approval and 2 years after the WHO recommended it for routine use. What interventions contributed to this rapid rollout, and what role did the PDP play?
methodsWe analysed the academic and grey literature, internal documents from TBA, and conducted interviews with 21 key informants from 16 organisations. We identified relevant interventions and actors, constructed a timeline and analysed the role TBA played.
resultsWe found TBA orchestrated a complex set of interventions implemented by dozens of actors over an 8-year time period across three categories: regulatory and normative guidance; market shaping for affordability and availability; and supporting country-level implementation through knowledge generation, knowledge sharing, stakeholder engagement and advocacy. Five attributes enabled TBA to do so: ability to generate and share knowledge about the product and regimen; non-profit status; ability to mobilise material resources for access interventions; pre-existing relationships and/or ability to develop new collaborative relationships; and intrinsic motivation to see the product reaching people with DR-TB.
conclusionAn orchestrator able to steer many actors towards the shared goal of reaching patients is critical in a complex ecosystem where no single organisation can realise access alone. Non-profit product developers can play this role well, including managing actual or perceived conflicts of interest, but require clearer mandates and financial support to do so.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.